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ABSTRACT 
The data on the role of chemokine genes (+1931A/T CCL4, A/G CXCL11 (rs4512021), -403A/G CCL5, C/G 
CCL2 (rs2857657), -801G/A CXCL12) in the formation of terminal stage of chronic renal failure,in patients with 
chronic glomerulonephritis,is presented in the work. It was established, that the allele A CXCL11 (rs4512021) 
(OR = 1.65) was the marker for the development of terminal stage of chronic renal insufficiency, and the genotype 
GG CXCL11was a protective factor for the development of terminal stage of chronic renal failure (OR = 0.22). 
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INTRODUCTION 
Chronic glomerulonephritis (CGN) is a 
multifactorial, genetically determined, immune-
mediated renal glomeruli disorder, which is 
accompanied by the development of renal 
failure, hypertension, and can lead to death, 
caused by chronic renal failure (Buraczynska et 
al., 2010; Kamyshova et al., 2016 ). 
At present, the involvement of genetic 
component in the formation, development and 
progression of renal pathologies, including 
chronic glomerulonephritis, is actively studied 
(Litovkina et al., 2014; Sorokina et al., 2016). 
The genes of renin-angiotensin-aldosterone 
system, the system of endothelial synthesis, as 
well as the genes of integral membrane proteins, 
tumor necrosis factors, interleukinsare mainly 
considered as candidate genesin nephrology 
(Buraczynska et al., 2010; Litovkina et al., 
2014). According to the literature data (Anders 
et al., 2010), chemokineshave significant 
importance in the development of CGN, 
activation of which occurs after triggering the 
chain of immune-inflammatory reactions. 
Chemokines control the migration of different 
types of leukocytes, having receptors from the 
bloodstream to the tissues, foci of inflammation, 
autoimmune process, participate in activation 
and differentiation of leukocytes, angiogenesis, 
fibrogenesis. Ultimately, these processes can 
invariably cause a violation of the normal 
functioning of kidney tissue, its hardening 
(Litovkina et al., 2014). In this regard, 
chemokine genes can be considered as potential 
candidate genes of CGN (Chow et al., 2007). 
The analysis of literature data allows to note, 
that the implication of genetic factors of 
chemokines in the development of renal 
pathologies, including chronic 
glomerulonephritis, has not been sufficiently 
studied to date, and the results of available 
scientific studies are very few and fragmentary 
(Piotrowski et al., 2010; Bagci et al., 2015). 
In accordance with the foregoing, the study of 
the role of polymorphic markers of chemokine 
genes ((+ 1931A/T CCL4, A/G CXCL11 
(rs4512021), -403A/G CCL5, C/G CCL2 
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(rs2857657), -801G/A CXCL12)) in the 
formation of terminal stage of chronic renal 
failure, in patients with chronic 
glomerulonephritis, was carried out in this work. 
 
MATERIALS AND METHODS 
The studied sample included 700 people: 238 
patients with chronic glomerulonephritis and 
462 persons were in the control group. 
Formation of samples of patient and control 
group was carried out using a continuous 
method, in the period from 2009 to 2011. The 
samplesincluded persons of Russian nationality, 
who were natives of the Central Chernozem 
Region of the Russian Federation, and were not 
related to each other. The investigated group of 
patients with CGN and the control group are 
comparable by gender, age characteristics, place 
of birth and nationality. 
Patients were included in the appropriate group 
only after making the diagnosis, confirmed with 
the help of clinical and laboratory-instrumental 
methods of examination. Clinical and laboratory 
examination of patients was carried out on the 
basis of Nephrology Department of the 
Belgorod Regional Clinical Hospital of St. 
Joasaph. All patients signed an informed consent 
for inclusion in the research and the use of 
obtained data. Ethical principles of the World 
Medical Association Declaration of Helsinki 
were adhered in the course of work with the 
surveyed persons. The control group included 
individuals without kidney disease and 
hypertension. 
Persons with hypertension and with a history of 
diabetes (or identified during the examination) 
were excluded from the group of patients. 
DNA samples were the material of the study. 
They were recovered from the whole venous 
blood, taken from the median cubital vein of 
proband, using the phenol-chloroform extraction 
method (Miller et al., 1988). Recovered DNA 
was used for performing the polymerase chain 
reaction (PCR) of DNA synthesis, using 
standard oligonucleotide primers and probes. 
Subsequent analysis of polymorphisms was 
carried out by the method of Taq-Man probes 
detection, with the help of real-time PCR. 
The analysis of association of alleles and 
genotypes of the studied DNA markers, with the 
formation of terminal stage of chronic renal 
failure, was carried out using conjugation tables 
2x2, with the calculation of the criterion2, with 
the Yates correction for continuity and odds 
ratio (OR), with 95% confidence intervals (CI). 
In the process of performing of multiple 
comparisons, with the aim to minimize errors of 
the first kind,connected with obtaining of false 
positive results, the Bonferronicorrection(pcor) 
was used. Statistical calculations were carried 
out using the program "STATISTICA 8.0". 
 
RESULTS AND DISCUSSION 
All patients with CGN and individuals in the 
control group were typed with five molecular-
genetic markers of chemokines: regulator of 
activity of T-cells normal expression (-403G/A 
CCL5), growth-promoting factor of β-cells 
precursors (-801G/A CXCL12), monocyte 
chemoattractant protein 1 (C/G CCL2, 
rs2857657), interferon inducible α 
chemoattractantofT-cells (A/G CXCL11, 
rs4512021), macrophage inflammatory protein 
1β (+ 1931A/T CCL4). 
The main characteristics of the studied group of 
patients with chronic glomerulonephritis and 
control group are presented in Table 1. The 
control group is fully comparable with the 
sample of patients with CGN, according to these 
characteristics (p> 0.05). 
In the process of comparative analysis of the 
frequencies of alleles and genotypes of the 
investigated loci, no statistically significant 
differences were found between CGN patients 
and the control group (p> 0.05). 
Further, we carried out a comparative analysis 
of the frequency distribution of alleles and 
genotypes of chemokine genes among patients, 
who reached the terminal stage of chronic renal 
failure (n = 71), and in the control group. The 
results of this study are presented in Table 2. It 
was found, that among patients with terminal 
stage of chronic renal failure, the concentration 
of genotype GG CXCL11 (rs 4512021) is 
5.08%, that is almost 4 times less, than the 
corresponding value in the control group 
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(19.69%, OR = 0.22, 95% CI 0.14-0.75, χ2 = 
6.57, p = 0.01,pcor= 0.03). 
Similar data were obtained on the alleles 
frequencies of the locus A/G CXCL11. Among 
patients with terminal stage of chronic renal 
failure, the frequency of the allele G 
CXCL11was 32.20%, whereas in the control 
group the prevalence of this marker was 43.96% 
(OR = 0.61, 95CI% 1.08-2.54, χ2 = 5.42, p = 
0.02). Revealed relationship between these 
genetic variants,with the formation of terminal 
stage of chronic renal failure in CGN patients, 
can be explained from the standpoint of their 
biomedical effects. It is known, that certain 
allelic variants of genes (usually "mutant" 
alleles) cause the increased production of 
corresponding cytokines (Sorokina et al., 2016), 
which will be clinically manifested by their 
more pronounced biomedical effects. According 
to the literature data, individuals with 4 and 5 
stages of chronic kidney disease (CKD) have 
higher concentration of CXCL11 in blood, than 
healthy individuals and patients with 1-3 stages 
of  CKD (Lebherz-Eichinger et al., 2014). 
Interferon inducible α-chemoattractant of T-cells 
is the most important chemotactic factor for T-
lymphocytes,itactivates Th1CD4 T-cells, NK 
cells, monocytes in the focus of inflammation 
(Teramoto et al., 2008). This can play an 
important role in maintaining of chronic 
inflammatory process in the kidney, causing a 
decline in its functioning, and also it can lead to 
the end-stage of chronic renal failure. 
 
CONCLUSION 
As a result of the study, it was established, that 
the allele A of interferon inducible α-
chemoattractant of T-cells (rs4512021) (OR = 
1.65) could be considered as a marker for the 
development of terminal stage of chronic renal 
failure in patients with chronic 
glomerulonephritis, and the genotype GG 
CXCL11was a protective factor of development 
of terminal stage of chronic renal failure (OR = 
0.22). 
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Tables 
Table 1.Characteristics of the subjects from the case and control groups. 
 
Characteristics Cases Controls 
Total 238  462 
Males 53.4%  53.7% 
Females 46.6% 46.4% 
Age, yrs 39.58 ±14.58 42.12 ± 5.19 
Weight, kg 63.4 ± 2.1 66.4 ± 2.0 
Height, cm 165.4 ± 3.4 169.5 ± 1.9 
 
Table 2. Distribution of genotypes of polymorphic loci of chemokines among patients with chronic 
glomerulonephritis with terminal stage of chronic renal failure and in the control group 
 
Polymorphism Control group (n=462) 
CGN patients with 
terminal stage of 
chronic renal failure 
(n=71) 
OR (95%CI) χ2 (р) 
Locus Genotype n % n % 
+1931А/ТСС
L4 
+1931AA 31 6,87 4 5,88 0,85 (0,25-1,03) χ2=0,02; p=0,96 
+1931AT 184 40,80 37 54,41 1,73 (1,01-2,98) χ2=3,94; p=0,05 
+1931TT 236 52,53 27 39,71 1,65 (0,08-2,54) χ2=3,27; p=0,07 
A/G CXCL11 
(rs 4512021) 
AA 142 31,76 24 40,68 1,52 (0,84-2,74) χ2=1,79; p=0,18 
AG 217 48,55 32 54,24 1,25(0,70-2,24) χ2=0,47; p=0,49 
GG 88 19,69 3 5,08 0,22 (0,14-0,75) χ2=6,57 p=0,01 
-403A/G 
CCL5 
-403GG 286 67,29 26 58,33 0,69 (0,38-1,23) χ2=1,50; p=0,22 
-403GA 126 29,65 35 40,00 1,58 (0,87-2,55) χ2=2,17; p=0,14 
-403AA 13 3,05 24 1,67 0,56 (0,02-4,24) χ2=0,01; p=0,89 
C/G CCL2 
(rs2857657) 
CC 313 68,34 44 64,71 0,86 (0,49-1,55) χ2=0,14; p=0,71 
GC 133 29,04 23 33,82 1,12 (0,61-2,03) χ2=0,06 p=0,79 
GG 12 2,62 1 1,47 1,31 (0,19-6,57) χ2=0,01; p=1,00 
-801G/A 
CXCL12 
- 801GG 320 71,11 47 68,12 0,85 (0,48-1,50) χ2=0,21; p=0,64 
- 801GA 120 26,67 20 28,99 1,25 (0,70-2,20) χ2=0,44; p=0,50 
- 801AA 10 2,22 2 2,89 0,56 (0,02-4,20) χ2=0,02; p=0,88 
Notes: n, sample size; CGN, chronic glomerulonephritis; OR, odds ratio; 95%CI, 95% confidence interval; P 
values were calculated using the χ2 test. 
 
 
 
